English Español

Immune-monitoring of haemophilia A patients undergoing ITI

Despite clinical experience with the different protocols of ITI, little is known about the immunological mechanisms that cause the downregulation of FVIII-specific immune responses and the induction of long-lasting immune tolerance against FVIII. S. Lacroix-Desmazes will monitor and analyze the modifications of the immune system and the inflammatory status of the patient during the course of ITI.

Hypothesis:

Some clinically relevant immune markers (IMs) might help to predict the positive or negative outcome of the ITI.
The FVIII-inhibitor plasma may be able to affect the differentiation and maturation state of dendritic cells from healthy blood donors.

Method:

Both, cells and plasma collected during the course of ITI therapy will be required to study the IMs in haemophilia A patients with inhibitors. Depending on the amount of blood collected, the IMs will be studied with the following priority:

Also, quantitative measurements of different interleukins involved in the immune response including INF-γ, TGF-β1 and TNF-α in plasma will be done.

Literature overview:

Sébastien Lacroix-Desmazes Sébastien Lacroix-Desmazes
Paris, France